Galectins as cancer biomarkers

Cancers

Volumn 2, Issue 2, 2010, Pages 592-610

  Balan, Vitaly ^a   Nangia Makker, Pratima ^a   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Biomarkers; Cancer; Galectins

Indexed keywords

ECALECTIN; GALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 4; GALECTIN 8;

BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; COLON CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GLIOMA; HUMAN; LUNG CANCER; LYMPHOMA; MELANOMA; MENINGIOMA; METASTASIS POTENTIAL; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THYROID CANCER;

EID: 79952273636     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2020592     Document Type: Review

References (93)

1. Dumic, J.; Dabelic, S.; Flögel, M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 2006, 1760, 616-635.
2. Vasta, G.R. Roles of galectins in infection. Nat. Rev. Microbiol. 2009, 7, 424-438.
3. Barondes, S.H.; Cooper, D.N.; Gitt, M.A.; Leffler, H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 1994, 269, 20807-20810.
4. Califice, S.; Castronovo, V.; Van Den Brule, F. Galectin-3 and cancer. Int. J. Oncol. 2004, 25, 983-992.
5. Ochieng, J.; Fridman, R.; Nangia-Makker, P.; Kleiner, D.E.; Liotta, L.A.; Stetler-Stevenson, W.G.; Raz, A. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry (Moscow) 1994, 33, 14109-14114.
6. Nagae, M.; Nishi, N.; Murata, T.; Usui, T.; Nakamura, T.; Wakatsuki, S.; Kato, R. Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J. Biol. Chem. 2006, 281, 35884-35893.
7. Rabinovich, G.A.; Liu, F.T.; Hirashima, M.; Anderson, A. An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand. J. Immunol. 2007, 66, 143-158.
8. Castronovo, V.; Van Den Brule, F.A.; Jackers, P.; Clausse, N.; Liu, F.T.; Gillet, C.; Sobel, M.E. Decreased expression of galectin-3 is associated with progression of human breast cancer. J. Pathol. 1996, 179, 43-48.
9. Idikio, H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int. J. Oncol. 1998, 12, 1287-1290.
10. Nangia-Makker, P.; Thompson, E.; Hogan, V.; Ochieng, J.; Raz, A. Induction of tumorigenicity by galectin-3 in a non-tumorigenic human breast carcinoma cell line. Int. J. Oncol. 1995, 7, 1079-1087.
11. Honjo, Y.; Nangia-Makker, P.; Inohara, H.; Raz, A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin. Cancer Res. 2001, 7, 661-668.
12. Shekhar, M.P.; Nangia-Makker, P.; Tait, L.; Miller, F.; Raz, A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am. J. Pathol. 2004, 165, 1931-1941.
13. Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41, 154-161.
14. Fernandez-Aguilar, S.; Noel, J.C. Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast. APMIS 2008, 116, 33-40.
15. Nangia-Makker, P.; Raz, T.; Tait, L.; Hogan, V.; Fridman, R.; Raz, A. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res. 2007, 67, 11760-11768.
16. Irie, A.; Yamauchi, A.; Kontani, K.; Kihara, M.; Liu, D.; Shirato, Y.; Seki, M.; Nishi, N.; Nakamura, T.; Yokomise, H.; Hirashima, M. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin. Cancer Res. 2005, 11, 2962-2968.
17. Huflejt, M.E.; Leffler, H. Galectin-4 in normal tissues and cancer. Glycoconj. J. 2004, 20, 247-255.
18. Balasubramanian, K.; Vasudevamurthy, R.; Venkateshaiah, S.U.; Thomas, A.; Vishweshwara, A.; Dharmesh, S.M. Galectin-3 in urine of cancer patients: stage and tissue specificity. J. Cancer Res. Clin. Oncol. 2009, 135, 355-363.
19. Heinzelmann-Schwarz, V.A.; Gardiner-Garden, M.; Henshall, S.M.; Scurry, J.P.; Scolyer, R.A.; Smith, A.N.; Bali, A.; Vanden Bergh, P.; Baron-Hay, S.; Scott, C.; Fink, D.; Hacker, N.F.; Sutherland, R.L.; O'Brien, P.M. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br. J. Cancer 2006, 94, 904-913.
20. Brustmann, H. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int. J. Gynecol. Pathol. 2008, 27, 380-389.
21. Cindolo, L.; Benvenuto, G.; Salvatore, P.; Pero, R.; Salvatore, G.; Mirone, V.; Prezioso, D.; Altieri, V.; Bruni, C.B.; Chiariotti, L. galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int. J. Cancer 1999, 84, 39-43.
22. Sakaki, M.; Oka, N.; Nakanishi, R.; Yamaguchi, K.; Fukumori, T.; Kanayama, H.O. Serum level of galectin-3 in human bladder cancer. J. Med. Invest. 2008, 55, 127-132.
23. Lotan, R.; Ito, H.; Yasui, W.; Yokozaki, H.; Lotan, D.; Tahara, E. Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int. J. Cancer 1994, 56, 474-480.
24. Baldus, S.E.; Zirbes, T.K.; Weingarten, M.; Fromm, S.; Glossmann, J.; Hanisch, F.G.; Monig, S.P.; Schroder, W.; Flucke, U.; Thiele, J.; Holscher, A.H.; Dienes, H.P. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol. 2000, 21, 258-266.
25. Miyazaki, J.; Hokari, R.; Kato, S.; Tsuzuki, Y.; Kawaguchi, A.; Nagao, S.; Itoh, K.; Miura, S. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol. Rep. 2002, 9, 1307-1312.
26. Kim, S.J.; Choi, I.J.; Cheong, T.C.; Lee, S.J.; Lotan, R.; Park, S.H.; Chun, K.H. Galectin-3 Increases Gastric Cancer Cell Motility by Up-Regulating Fascin-1 Expression. Gastroenterology 2009, 138, 1035-1045.
27. Hippo, Y.; Yashiro, M.; Ishii, M.; Taniguchi, H.; Tsutsumi, S.; Hirakawa, K.; Kodama, T.; Aburatani, H. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 2001, 61, 889-895.
28. Endo, K.; Kohnoe, S.; Tsujita, E.; Watanabe, A.; Nakashima, H.; Baba, H.; Maehara, Y. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005, 25, 3117-3121.
29. Nagy, N.; Legendre, H.; Engels, O.; André, S.; Kaltner, H.; Wasano, K.; Zick, Y.; Pector, J.-C.; Decaestecker, C.; Gabius, H.-J.; Salmon, I.; Kiss, R. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003, 97, 1849-1858.
30. Hittelet, A.; Legendre, H.; Nagy, N.; Bronckart, Y.; Pector, J.-C.; Salmon, I.; Yeaton, P.; Gabius, H.-J.; Kiss, R.; Camby, I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int. J. Cancer 2003, 103, 370-379.
31. Greco, C.; Vona, R.; Cosimelli, M.; Matarrese, P.; Straface, E.; Scordati, P.; Giannarelli, D.; Casale, V.; Assisi, D.; Mottolese, M.; Moles, A.; Malorni, W. Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions. Glycobiology 2004, 14, 783-792.
32. Schoeppner, H.L.; Raz, A.; Ho, S.B.; Bresalier, R.S. Expression of an endogenous galactosebinding lectin correlates with neoplastic progression in the colon. Cancer 1995, 75, 2818-2826.
33. Nakamura, M.; Inufusa, H.; Adachi, T.; Aga, M.; Kurimoto, M.; Nakatani, Y.; Wakano, T.; Nakajima, A.; Hida, J.I.; Miyake, M.; Shindo, K.; Yasutomi, M. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int. J. Oncol. 1999, 15, 143-148.
34. van den Brule, F.A.; Buicu, C.; Berchuck, A.; Bast, R.C.; Deprez, M.; Liu, F.T.; Cooper, D.N.; Pieters, C.; Sobel, M.E.; Castronovo, V. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum. Pathol. 1996, 27, 1185-1191.
35. Lotz, M.M.; Andrews, C.W., Jr.; Korzelius, C.A.; Lee, E.C.; Steele, G.D., Jr.; Clarke, A.; Mercurio, A.M. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc. Natl. Acad. Sci. USA 1993, 90, 3466-3470.
36. Bidon-Wagner, N.; Le Pennec, J.P. Human galectin-8 isoforms and cancer. Glycoconj. J. 2004, 19, 557-563.
37. Vereecken, P.; Debray, C.; Petein, M.; Awada, A.; Lalmand, M.C.; Laporte, M.; Van Den Heule, B.; Verhest, A.; Pochet, R.; Heenen, M. Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch. Dermatol. Res. 2005, 296, 353-358.
38. Vereecken, P.; Zouaoui Boudjeltia, K.; Debray, C.; Awada, A.; Legssyer, I.; Sales, F.; Petein, M.; Vanhaeverbeek, M.; Ghanem, G.; Heenen, M. High serum galectin-3 in advanced melanoma: preliminary results. Clin. Exp. Dermatol. 2006, 31, 105-109.
39. Vereecken, P.; Awada, A.; Suciu, S.; Castro, G.; Morandini, R.; Litynska, A.; Lienard, D.; Ezzedine, K.; Ghanem, G.; Heenen, M. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res. 2009, 19, 316-320.
40. Prieto, V.G.; Mourad-Zeidan, A.A.; Melnikova, V.; Johnson, M.M.; Lopez, A.; Diwan, A.H.; Lazar, A.J.; Shen, S.S.; Zhang, P.S.; Reed, J.A.; Gershenwald, J.E.; Raz, A.; Bar-Eli, M. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin. Cancer Res. 2006, 12, 6709-6715.
41. Ellerhorst, J.; Troncoso, P.; Xu, X.C.; Lee, J.; Lotan, R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol. Res. 1999, 27, 362-367.
42. Pacis, R.A.; Pilat, M.J.; Pienta, K.J.; Wojno, K.; Raz, A.; Hogan, V.; Cooper, C.R. Decreased galectin-3 expression in prostate cancer. Prostate 2000, 44, 118-123.
43. van den Brule, F.A.; Waltregny, D.; Castronovo, V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J. Pathol. 2001, 193, 80-87.
44. van den Brule, F.A.; Waltregny, D.; Liu, F.T.; Castronovo, V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int. J. Cancer 2000, 89, 361-367.
45. Ahmed, H.; Banerjee, P.P.; Vasta, G.R. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem. Biophys. Res. Commun. 2007, 358, 241-246.
46. Wang, Y.; Nangia-Makker, P.; Tait, L.; Balan, V.; Hogan, V.; Pienta, K.J.; Raz, A. Regulation of prostate cancer progression by galectin-3. Am. J. Pathol. 2009, 174, 1515-1523.
47. Yoshimura, A.; Gemma, A.; Hosoya, Y.; Komaki, E.; Hosomi, Y.; Okano, T.; Takenaka, K.; Matuda, K.; Seike, M.; Uematsu, K.; Hibino, S.; Shibuya, M.; Yamada, T.; Hirohashi, S.; Kudoh, S. Increased expression of the LGALS3 (galectin 3) gene in human non-small-cell lung cancer. Gen. Chrom. Cancer 2003, 37, 159-164.
48. Buttery, R.; Monaghan, H.; Salter, D.M.; Sethi, T. Galectin-3: differential expression between small-cell and non-small-cell lung cancer. Histopathology 2004, 44, 339-344.
49. Jeong, S.H.; Lee, H.W.; Han, J.H.; Kang, S.Y.; Choi, J.H.; Jung, Y.M.; Choi, H.; Oh, Y.T.; Park, K.J.; Hwang, S.C.; Sheen, S.S.; Oh, Y.J.; Kim, J.H.; Lim, H.Y. Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology. Jpn. J. Clin. Oncol. 2008, 38, 661-669.
50. Szoke, T.; Kayser, K.; Baumhakel, J.D.; Trojan, I.; Furak, J.; Tiszlavicz, L.; Horvath, A.; Szluha, K.; Gabius, H.J.; Andre, S. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 2005, 69, 167-174.
51. Szoke, T.; Kayser, K.; Trojan, I.; Kayser, G.; Furak, J.; Tiszlavicz, L.; Baumhakel, J.D.; Gabius, H.J. The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II. Eur. J. Cardiothorac. Surg. 2007, 31, 783-787.
52. Puglisi, F.; Minisini, A.M.; Barbone, F.; Intersimone, D.; Aprile, G.; Puppin, C.; Damante, G.; Paron, I.; Tell, G.; Piga, A.; Di Loreto, C. Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett. 2004, 212, 233-239.
53. Iurisci, I.; Tinari, N.; Natoli, C.; Angelucci, D.; Cianchetti, E.; Iacobelli, S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 2000, 6, 1389-1393.
54. Henno, S.; Brichory, F.; Langanay, T.; Desrues, B.; Bidon, N.; Delaval, P.; Ramee, M.P.; Dazord, L.; Caulet-Maugendre, S. Expression of Po66-CBP, a galectin-8, in different types of primary and secondary broncho-pulmonary tumors. Oncol. Rep. 2002, 9, 177-180.
55. Caulet-Maugendre, S.; Birolleau, S.; Corbineau, H.; Bassen, R.; Desrues, B.; Bidon, N.; Delaval, P.; Ramee, M.P.; Brichory, F.; Dazord, L. Immunohistochemical expression of the intracellular component of galectin-8 in squamous cell metaplasia of the bronchial epithelium in neoplastic and benign processes. Pathol. Res. Pract. 2001, 197, 797-801.
56. Konstantinov, K.N.; Robbins, B.A.; Liu, F.T. Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma. Am. J. Pathol. 1996, 148, 25-30.
57. Kim, S.J.; Lee, S.J.; Sung, H.J.; Choi, I.K.; Choi, C.W.; Kim, B.S.; Kim, J.S.; Yu, W.; Hwang, H.S.; Kim, I.S. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol. 2008, 120, 211-216.
58. Bresalier, R.S.; Yan, P.S.; Byrd, J.C.; Lotan, R.; Raz, A. Expression of the endogenous galactosebinding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 1997, 80, 776-787.
59. Gordower, L.; Decaestecker, C.; Kacem, Y.; Lemmers, A.; Gusman, J.; Burchert, M.; Danguy, A.; Gabius, H.; Salmon, I.; Kiss, R.; Camby, I. Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol. Appl. Neurobiol. 1999, 25, 319-330.
60. Strik, H.M.; Deininger, M.H.; Frank, B.; Schluesener, H.J.; Meyermann, R. Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J. Neurooncol. 2001, 53, 13-20.
61. Das, A.; Tan, W.L.; Smith, D.R. Expression of extracellular matrix markers in benign meningiomas. Neuropathology 2003, 23, 275-281.
62. Park, S.H.; Min, H.S.; Kim, B.; Myung, J.; Paek, S.H. Galectin-3: a useful biomarker for differential diagnosis of brain tumors. Neuropathology 2008, 28, 497-506.
63. Schaffert, C.; Pour, P.M.; Chaney, W.G. Localization of galectin-3 in normal and diseased pancreatic tissue. Int. J. Pancreatol. 1998, 23, 1-9.
64. Berberat, P.O.; Friess, H.; Wang, L.; Zhu, Z.; Bley, T.; Frigeri, L.; Zimmermann, A.; Buchler, M.W. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J. Histochem. Cytochem. 2001, 49, 539-549.
65. Shimamura, T.; Sakamoto, M.; Ino, Y.; Shimada, K.; Kosuge, T.; Sato, Y.; Tanaka, K.; Sekihara, H.; Hirohashi, S. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin. Cancer Res. 2002, 8, 2570-2575.
66. Chung, J.C.; Oh, M.J.; Choi, S.H.; Bae, C.D. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J. Surg. 2008, 78, 245-251.
67. Gillenwater, A.; Xu, X.C.; el-Naggar, A.K.; Clayman, G.L.; Lotan, R. Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996, 18, 422-432.
68. Piantelli, M.; Iacobelli, S.; Almadori, G.; Iezzi, M.; Tinari, N.; Natoli, C.; Cadoni, G.; Lauriola, L.; Ranelletti, F.O. Lack of expression of galectin-3 is associated with a poor outcome in nodenegative patients with laryngeal squamous-cell carcinoma. J. Clin. Oncol. 2002, 20, 3850-3856.
69. Plzak, J.; Smetana, K., Jr.; Hrdlickova, E.; Kodet, R.; Holikova, Z.; Liu, F.T.; Dvorankova, B.; Kaltner, H.; Betka, J.; Gabius, H.J. Expression of galectin-3-reactive ligands in squamous cancer and normal epithelial cells as a marker of differentiation. Int. J. Oncol. 2001, 19, 59-64.
70. Plzak, J.; Betka, J.; Smetana, K., Jr.; Chovanec, M.; Kaltner, H.; Andre, S.; Kodet, R.; Gabius, H.J. Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma. Eur. J. Cancer 2004, 40, 2324-2330.
71. Betka, J.; Plzak, J.; Smetana, K., Jr.; Gabius, H.J. Galectin-3, an endogenous lectin, as a tool for monitoring cell differentiation in head and neck carcinomas with implications for lectin-glycan functionality. Acta Otolaryngol. 2003, 123, 261-263.
72. Saussez, S.; Decaestecker, C.; Mahillon, V.; Cludts, S.; Capouillez, A.; Chevalier, D.; Vet, H.K.; Andre, S.; Toubeau, G.; Leroy, X.; Gabius, H.J. Galectin-3 upregulation during tumor progression in head and neck cancer. Laryngoscope 2008, 118, 1583-1590.
73. Chovanec, M.; Smetana, K., Jr.; Plzak, J.; Betka, J.; Plzakova, Z.; Stork, J.; Hrdlickova, E.; Kuwabara, I.; Dvorankova, B.; Liu, F.T.; Kaltner, H.; Andre, S.; Gabius, H.J. Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia. Prague Med. Rep. 2005, 106, 209-216.
74. Saussez, S.; Lorfevre, F.; Lequeux, T.; Laurent, G.; Chantrain, G.; Vertongen, F.; Toubeau, G.; Decaestecker, C.; Kiss, R. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 2008, 44, 86-93.
75. Xu, X.C.; el-Naggar, A.K.; Lotan, R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am. J. Pathol. 1995, 147, 815-822.
76. A.; Gasbarri, A.; Papotti, M.; Bussolati, G.; Lucante, T.; Khan, A.; Inohara, H.; Marandino, F.; Orlandi, F.; Nardi, F.; Vecchione, A.; Tecce, R.; Larsson, O.; Group, T.C.S. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001, 357, 1644-1650.
77. Orlandi, F.; Saggiorato, E.; Pivano, G.; Puligheddu, B.; Termine, A.; Cappia, S.; De Giuli, P.; Angeli, A. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998, 58, 3015-3020.
78. Lloyd, R.V. Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate. Endocr. Pathol. 2001, 12, 255-257.
79. Aratake, Y.; Umeki, K.; Kiyoyama, K.; Hinoura, Y.; Sato, S.; Ohno, A.; Kuribayashi, T.; Hirai, K.; Nabeshima, K.; Kotani, T. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn. Cytopathol. 2002, 26, 366-372.
80. Beesley, M.F.; McLaren, K.M. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002, 41, 236-243.
81. Coli, A.; Bigotti, G.; Zucchetti, F.; Negro, F.; Massi, G. Galectin-3, a marker of welldifferentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 2002, 40, 80-87.
82. Niedziela, M.; Maceluch, J.; Korman, E. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J. Clin. Endocrinol. Metab. 2002, 87, 4411-4415.
83. Oestreicher-Kedem, Y.; Halpern, M.; Roizman, P.; Hardy, B.; Sulkes, J.; Feinmesser, R.; Stern, Y. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 2004, 26, 960-966.
84. Mehrotra, P.; Okpokam, A.; Bouhaidar, R.; Johnson, S.J.; Wilson, J.A.; Davies, B.R.; Lennard, T.W.J. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004, 45, 493-500.
85. Mills, L.J.; Poller, D.N.; Yiangou, C. Galectin-3 is not useful in thyroid FNA. Cytopathology 2005, 16, 132-138.
86. Than, T.H.; Swethadri, G.K.; Wong, J.; Ahmad, T.; Jamil, D.; Maganlal, R.K.; Hamdi, M.M.; Abdullah, M.S. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Singapore Med. J. 2008, 49, 333-338.
87. Liu, Y.Y.; Morreau, H.; Kievit, J.; Romijn, J.A.; Carrasco, N.; Smit, J.W. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur. J. Endocrinol. 2008, 158, 375-384.
88. Rydlova, M.; Ludvikova, M.; Stankova, I. Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. Biomed. Pap. of the Med. Fac. Univ. Palacký 2008, 152, 53-59.
89. Saussez, S.; Glinoer, D.; Chantrain, G.; Pattou, F.; Carnaille, B.; Andre, S.; Gabius, H.J.; Laurent, G. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 2008, 18, 705-712.
90. Bartolazzi, A.; Orlandi, F.; Saggiorato, E.; Volante, M.; Arecco, F.; Rossetto, R.; Palestini, N.; Ghigo, E.; Papotti, M.; Bussolati, G.; Martegani, M.P.; Pantellini, F.; Carpi, A.; Giovagnoli, M.R.; Monti, S.; Toscano, V.; Sciacchitano, S.; Pennelli, G.M.; Mian, C.; Pelizzo, M.R.; Rugge, M.; Troncone, G.; Palombini, L.; Chiappetta, G.; Botti, G.; Vecchione, A.; Bellocco, R. Galectin-3- expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fineneedle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008, 9, 543-549.
91. Wiseman, S.M.; Melck, A.; Masoudi, H.; Ghaidi, F.; Goldstein, L.; Gown, A.; Jones, S.J.; Griffith, O.L. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann. Surg. Oncol. 2008, 15, 2811-2826.
92. Griffith, O.L.; Chiu, C.G.; Gown, A.M.; Jones, S.J.; Wiseman, S.M. Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev. Anticancer Ther. 2008, 8, 1399-1413.
93. Balan, V.; Nangia-Makker, P.; Schwartz, A.G.; Jung, Y.S.; Tait, L.; Hogan, V.; Raz, T.; Wang, Y.; Yang, Z.Q.; Wu, G.S.; Guo, Y.; Li, H.; Abrams, J.; Couch, F.J.; Lingle, W.L.; Lloyd, R.V.; Ethier, S.P.; Tainsky, M.A.; Raz, A. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res. 2008, 68, 10045-10050.